{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:46:07Z","timestamp":1793637967596,"version":"4.5.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bristol-Myers Squibb Company"},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015542","name":"GlaxoSmithKline K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JMDC, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-96579-2","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T15:55:20Z","timestamp":1744300520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A real-world descriptive study of screening practices for hydroxychloroquine retinopathy in Japan using an insurance claims database"],"prefix":"10.1038","volume":"15","author":[{"given":"Kumiko","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Yokogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineo","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"96579_CR1","doi-asserted-by":"crossref","unstructured":"Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum. 42, 1785\u20131796 (1999).","DOI":"10.1002\/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-#"},{"key":"96579_CR2","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor, M. F., Kellner, U., Lai, T. Y., Melles, R. B. & Mieler, W. F.; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123, 1386\u20131394 (2016).","journal-title":"Ophthalmology"},{"key":"96579_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann. Rheum. Dis. 83, 15\u201329 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"96579_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/art.40018","volume":"69","author":"N Yokogawa","year":"2017","unstructured":"Yokogawa, N. et al. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: A multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol. 69, 791\u2013799 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"96579_CR5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaophthalmol.2014.1099","volume":"132","author":"MF Marmor","year":"2014","unstructured":"Marmor, M. F. & Hu, J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol. 132, 1105\u20131112 (2014).","journal-title":"JAMA Ophthalmol."},{"key":"96579_CR6","unstructured":"Sanofi K. K. & Asahi Kasei Pharma Corporation. Plaquenil\u00ae Tablets package insert (2024)."},{"key":"96579_CR7","unstructured":"Kondo, M., Shinoda, K., Matsumoto, C. S., Yokogawa, N. & Terasaki, H. Guide for clinical use of hydroxychloroquine. Nihon Ganka Gakkai Zasshi 120, 419\u2013428 (2016)."},{"key":"96579_CR8","unstructured":"Japan College of Rheumatology & Japanese Dermatological Association. Guidance for Proper Use of Hydroxychloroquine (Simplified Version). https:\/\/www.ryumachi-jp.com\/info\/guideline_hcq.pdf. (in Japanese; accessed 7 October 2024)."},{"key":"96579_CR9","unstructured":"The Royal Australian and New Zealand College of Ophthalmologists. Guidelines for Screening for Hydroxychloroquine Retinopathy. https:\/\/ranzco.edu\/wp-content\/uploads\/2021\/04\/RANZCO-Guidelines-for-screening-for-HCQ-Retinopathy.pdf. (accessed 7 October 2024)."},{"key":"96579_CR10","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/s41433-020-01380-2","volume":"35","author":"IH Yusuf","year":"2021","unstructured":"Yusuf, I. H., Foot, B. & Lotery, A. J. The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary. Eye 35, 1532\u20131537 (2021).","journal-title":"Eye"},{"key":"96579_CR11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s10384-021-00841-9","volume":"65","author":"H Ozawa","year":"2021","unstructured":"Ozawa, H. et al. Ocular findings in Japanese patients with hydroxychloroquine retinopathy developing within 3 years of treatment. Jpn. J. Ophthalmol. 65, 472\u2013481 (2021).","journal-title":"Jpn. J. Ophthalmol."},{"key":"96579_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ajo.2015.06.009","volume":"160","author":"A Au","year":"2015","unstructured":"Au, A. et al. Hydroxychloroquine screening practice patterns within a large multispecialty ophthalmic practice. Am. J. Ophthalmol. 160, 561-568.e2 (2015).","journal-title":"Am. J. Ophthalmol."},{"key":"96579_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/24741264221097806","volume":"6","author":"YFK Islam","year":"2022","unstructured":"Islam, Y. F. K., Stroman, W. R. & Steigleman, W. A. Compliance with hydroxychloroquine screening guidelines at a large academic medical center. J. Vitreoretin. Dis. 6, 271\u2013277 (2022).","journal-title":"J. Vitreoretin. Dis."},{"key":"96579_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14816","volume":"6","author":"J Kim","year":"2023","unstructured":"Kim, J., Kim, K. E., Kim, J. H. & Ahn, S. J. Practice patterns of screening for hydroxychloroquine retinopathy in South Korea. JAMA Netw. Open 6, e2314816 (2023).","journal-title":"JAMA Netw. Open"},{"key":"96579_CR15","doi-asserted-by":"publisher","first-page":"e15122","DOI":"10.1097\/MD.0000000000015122","volume":"98","author":"CY Yen","year":"2019","unstructured":"Yen, C. Y. et al. Current screening practice in patients under long-term hydroxychloroquine medication in Taiwan: A nationwide population-based cohort study. Medicine 98, e15122 (2019).","journal-title":"Medicine"},{"key":"96579_CR16","first-page":"817","volume":"43","author":"A Tomura","year":"2022","unstructured":"Tomura, A. & Usami, M. Safety and effectiveness of hydroxychloroquine in Japanese people with cutaneous lupus erythematosus and systemic lupus erythematosus: Results of a drug use\u2013results survey. Ther. Res. 43, 817\u2013842 (2022).","journal-title":"Ther. Res."},{"key":"96579_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ajo.2024.07.028","volume":"268","author":"M Rahmati","year":"2024","unstructured":"Rahmati, M. et al. Factors affecting global adherence for the uptake of diabetic retinopathy screening: A systematic review and meta-analysis. Am. J. Ophthalmol. 268, 94\u2013107 (2024).","journal-title":"Am. J. Ophthalmol."},{"key":"96579_CR18","unstructured":"JMDC Inc. JMDC Claims Database. https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database\/. (accessed 7 October 2024)."},{"key":"96579_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/jgf2.422","volume":"22","author":"K Nagai","year":"2021","unstructured":"Nagai, K. et al. Data resource profile: JMDC claims database sourced from health insurance societies. J. Gen. Fam. Med. 22, 118\u2013127 (2021).","journal-title":"J. Gen. Fam. Med."},{"key":"96579_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41598-024-51667-7","volume":"14","author":"J Kim","year":"2024","unstructured":"Kim, J., Jeong, H. C., Kwon, H. Y., Kim, Y. H. & Ahn, S. J. Demographic and clinical characteristics associated with screening practices for hydroxychloroquine retinopathy. Sci. Rep. 14, 974 (2024).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96579-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96579-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96579-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T15:55:25Z","timestamp":1744300525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96579-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96579"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96579-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kumiko Kato declares no competing interests; Mineo Kondo declares no competing interests; Kei Shinoda declares no competing interests; Naoto Yokogawa declares receiving speaker fees from Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., and Asahi Kasei Pharma Corporation; Takumi Tajima is an employee of JMDC, Inc.; and Toshiya Takahashi is an employee of Asahi Kasei Pharma Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The data source for this study was an anonymized, de-identified\/de-linked secondary database that was used only for research purposes by the database vendor and was not linked to individual patient medical records. The requirement for informed consent was waived, and an opt-out approach was applied in compliance with local regulations. The study adhered to the principles of the Declaration of Helsinki. Ethical approval was not obtained because local regulations do not require it for studies utilizing pre-existing anonymized, de-identified\/de-linked databases.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"12330"}}